INT8099

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1992
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 3.09
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (ERBB3) extracellular space (ERBB3) extracellular region (ERBB3)
plasma membrane (ERBB3) nucleus (ERBB3)
Anatomy Link Frequency
arm 1
MDA-MB-231 1
ERBB3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Chronic pancreatitis 1 83.52 Quite High
palliative 4 32.16 Quite Low
psoriasis 3 13.92 Low Low
member 8 2 8.20 Low Low
Central nervous system 21 5.00 Very Low Very Low Very Low
imagery 9 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
antagonist 3 5.00 Very Low Very Low Very Low
metalloproteinase 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 378 99.66 Very High Very High Very High
Cancer 225 99.52 Very High Very High Very High
Solid Tumor 2 98.92 Very High Very High Very High
Hyperplasia 8 91.52 High High
Pancreatic Cancer 3 90.84 High High
Carcinoma 6 87.28 High High
Shock 1 87.04 High High
Congenital Anomalies 1 86.60 High High
Pancreatitis 1 83.52 Quite High
Disease 127 78.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A third member of this receptor family, erbB-3, has recently been recognized and found to be abnormally expressed in some types of human cancer.
erbB-3 Binding (recognized) of associated with cancer
1) Confidence 0.36 Published 1992 Journal J. Pathol. Section Abstract Doc Link 1361525 Disease Relevance 0.52 Pain Relevance 0.08
For example, ErbB3, fos, TGF?
ErbB3 Binding (example) of
2) Confidence 0.35 Published 2005 Journal BMC Cancer Section Body Doc Link PMC1182358 Disease Relevance 0.41 Pain Relevance 0
MDA-MB-231 genome
MDA-MB-231 Binding (genome) of in MDA-MB-231
3) Confidence 0.24 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1413994 Disease Relevance 0 Pain Relevance 0
Pertuzumab has been shown to bind to the dimerization arm of HER2, blocking HER2/HER3 heterodimerization and attenuating growth of solid tumors in model systems [133].
HER3 Binding (heterodimerization) of in arm associated with solid tumor
4) Confidence 0.20 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.57 Pain Relevance 0
Molecular interactions between HER2 and other members of its family (HER1 or EGFR, HER3 and HER4) have led to the development of new targeted therapies such as the anti-EGFR monoclonal antibody cetuximab, the anti-EGFR oral small molecule tyrosine kinase inhibitors erlotinib and gefitinib, and the dual EGFR-HER2 tyrosine kinase inhibitor lapatinib [96].
HER3 Binding (interactions) of
5) Confidence 0.17 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.57 Pain Relevance 0
The major oncogenic unit in HER2-positive breast cancer appears to be a heterodimer between the HER2 and epidermal growth factor receptor-3 (HER3) proteins, where HER3 functions as a necessary dimerization partner for HER2 to achieve full oncogenic signaling potential [131].
HER3 Binding (heterodimer) of associated with breast cancer
6) Confidence 0.15 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.75 Pain Relevance 0
ErbB2, whilst having no exogenous ligand, is the preferred partner for heterodimerization with ErbB1, ErbB3 and ErbB4 as it amplifies the mitogenic signal with potent growth and survival effects.
ErbB3 Binding (heterodimerization) of
7) Confidence 0.14 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox